Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Canada Cancer and Aging Research Laboratory (CCARL) Launched in Lethbridge to Provide Personalized Diagnostic and Medical Solutions for Cancer and Age-Related Diseases
  • USA - English


News provided by

CCARL

Oct 07, 2014, 19:25 ET

Share this article

Share toX

Share this article

Share toX

Lethbridge, AB, Canada (PRWEB) October 07, 2014 -- Canada Cancer and Aging Research Laboratory (CCARL) today announced the launch of its personalized medicine and research programs in Canada. The company plans to unfold its operations in two phases, working in the areas of a personalized medical approach for cancer treatment and combating aging and age-related diseases. During the first phase, the company aims to develop its partnership with Pathway Pharmaceuticals in Hong Kong to offer the OncoFinder (TM) technology in Canada. The OncoFinder (TM) system is a new revolutionary platform used to improve decision-making in personalized medicine of cancer and to increase the chances of selecting the right therapy for each patient. The platform maps the gene expression data from an individual patient’s tumor biopsy or a paraffin block onto a set of intracellular signaling pathways, measures the activation state of each individual pathway, and uses the activation signature of the resulting signaling pathway to predict the efficacy of various chemotherapy regiments and targeted drugs.

"CCARL draws on the strengths of its founders, Drs. Olga and Igor Kovalchuk, Professors and group leaders at the University of Lethbridge, who have established a solid reputation in genetic and epigenetic research of cancer and have been very instrumental in establishing and operating the next generation sequencing platform in Lethbridge. “We decided to go into business with the CCARL team because of their outstanding productivityand solid expertize," said Anton Buzdin, PhD, DSc, CEO of Pathway Pharmaceuticals, Ltd, in Hong Kong.

Over the past several decades, progress in biomedical sciences resulted in the development of many targeted drugs and chemotherapy regiments that work very well in certain patient groups, often resulting in the extended periods of remission or a complete cure. However, these therapeutic regiments are usually very expensive and often work in limited patient groups causing unnecessary and toxic treatments that degrade patients’ health and even encourage cancer to progress. Just as no two people are similar, no two cancers are alike, and there is a lot of variation even within the same tumor. Therefore, ideal therapeutic regiments targeting every cancer cell in the body must be tailored individually for each patient. Unlike many other methods, the OncoFinder system allows scientists to make better sense of the genetic background of each individual patient’s tumor, to compare it to the healthy state and rank the selected therapies by their predicted effectiveness.

In the second phase of operations, the company will develop tools for personalized medicine of other age-related diseases, including multiple sclerosis and Parkinson’s disease. The company plans to develop an analogue of OncoFinder that will consider the tissue-specific epigenetic changes in disease and aging processes for both disease treatment and prevention.

Co-founders of the company, Drs. Olga and Igor Kovalchuk, completed their post-doctoral work at the Friedrich Miescher Institute for Biomedical Research and Novartis (Basel, Switzerland) where they worked as visiting fellows and postdocs. For the past 20 years, Drs. Kovalchuks have been working in the area of genetics and epigenetics of genome stability and DNA repair.

Olga’s expertise and vision of aging research was well received recently at the “Practical Applications of Aging Research for Drug Development Aging” forum, a part of MipTec 2014, Europe’s largest drug discovery conference in Basel, Switzerland where she gave a talk titled “Applied Epigenetics of Aging and Longevity."

“Many cancer and aging pathways are interrelated, and the understanding of the interplay between pathologic and defensive pathways at the tissue-specific level is essential for developing effective interventions. We have decided to start with a reliable tool that we believe works well for predicting the efficacy of chemotherapy for individual patients and then to extrapolate this approach to other age-related diseases. In addition to selecting a perfect treatment for each individual patient, we want to develop personalized preventative regiments that would minimize the risk of cancer, other age-related diseases, and aging itself. We are researchers at heart and will continue working hard in academia. But instead of relying purely on government funding, we would like to use commercial funding for helping physicians make better clinical decisions and increase their patients’ life spans," said Olga Kovalchuk, CEO of CCARL.
About CCARL
Canada Cancer and Aging Research Laboratory (CCARL) is, the Alberta-based company in Lethbridge aiming to accelerate progress in personalized medicine of cancer and other age-related diseases. The company has licensed the OncoFinder platform to provide decision-support services to physicians and clinical institutions looking for improving the outcomes and reducing the costs associated with cancer treatment therapy. The company is also developing tools for personalized medicine of various age-related diseases and aging itself.

Contact:

Olga Kovalchuk, MD, PhD
olga.kovalchuk(at)ccarl(dot)ca /403 394 3916

Olga Kovalchuk, CCARL, http://www.ccarl.ca, +1 4033943916, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.